論文 - 松元　一明

Pharmacokinetics of prophylactic ampicillin-sulbactam and dosing optimization in patients undergoing cardiovascular surgery with cardiopulmonary bypass.

Yuta Yokoyama, Kazuaki Matsumoto, Kazuro Ikawa, Erika Watanabe, HiroyukiYamamoto, Yutaka Imoto, Norifumi Morikawa, Yasuo Takeda.

BIOLOGICAL & PHARMACEUTICAL BULLETIN 38   1817 - 1821 2015年11月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  0918-6158

Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.

Erika Watanabe, Takuro Nishikawa, Kazuro Ikawa, Hiroki Yamaguchi, Takanari Abematsu, Shunsuke Nakagawa, Koichiro Kurauchi, Yuichi Kodama, Takayuki Tanabe, Yuichi Shinkoda, Kazuaki Matsumoto, Yasuhiro Okamoto, Yasuo Takeda, Yoshifumi Kawano.

INTERNATIONAL JOURNAL OF HEMATOLOGY 102   611 - 616 2015年11月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  0925-5710

溶出性・分割性からみた市販アセトアミノフェン坐剤の比較.

黒田裕子, 徳田真実, 井上舞鳥, 増田克哉, 寺島朝子, 前澤佳代子, 松元一明, 木津純子.

医療薬学 41   714 - 721 2015年10月

研究論文（学術雑誌）, 共著, 査読有り

Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis.

Shinji Kawano, Kazuaki Matsumoto, Ryohei Hara, Yuko Kuroda, Kazuro Ikawa, Norifumi Morikawa, Tetsuya Horino, Seiji Hori, Junko Kizu.

JOURNAL OF INFECTION AND CHEMOTHERAPY 21   476 - 478 2015年06月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  1341-321X

Pharmacokinetics and skin tissue penetration of daptomycin in rats.

Kazuaki Matsumoto, Masashi Kitaoka, Yuko Kuroda, Kazuro Ikawa, Norifumi Morikawa, Junichi Sasaki, Osamu Iketani, Satoshi Iwata, Tetsuya Horino, Seiji Hori, Junko Kizu.

CLINICAL PHARMACOLOGY: ADVANCES AND APPLICATIONS 7   79 - 82 2015年05月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  1179-1438

医薬品副作用被害救済制度からみた一般用医薬品が関連した副作用被害の実態.

黒田裕子, 松元一明, 木津純子.

日本病院薬剤師会雑誌 51   425 - 428 2015年04月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  1341-8815

Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.

Yokoyama Yuta, Matsumoto Kazuaki, Ikawa Kazuro, Watanabe Erika, Morikawa Norifumi, Takeda Yasuo.

JOURNAL OF INFECTION AND CHEMOTHERAPY 21   284 - 289 2015年04月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  1341-321X

Risk factors for ganciclovir-induced thrombocytopenia and leukopenia.

Matsumoto Kazuaki, Shigemi Akari, Ikawa Kazuro, Kanazawa Naoko, Fujisaki Yuko, Morikawa Norifumi, Takeda Yasuo.

BIOLOGICAL & PHARMACEUTICAL BULLETIN 38   235 - 238 2015年02月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  0918-6158

バンコマイシン塩酸塩点滴静注用製剤の生理食塩液に対する溶解性比較.

松元一明, 黒田裕子, 寺島朝子, 前澤佳代子, 木津純子.

日本環境感染学会誌 30 （ 1 ） 29 - 32 2015年01月

研究論文（学術雑誌）, 共著, 査読有り

Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics.

Matsumoto Kazuaki, Shigemi Akari, Takeshita Ayumi, Watanabe Erika, Yokoyama Yuta, Ikawa Kazuro, Morikawa Norifumi, Takeda Yasuo.

JOURNAL OF INFECTION AND CHEMOTHERAPY （SPRINGER JAPAN KK）  21 （ 1-2 ） 70 - 73 2015年01月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  1341-321X

　概要を見る

Linezolid pharmacokinetic profile in pediatric patients has not been fully characterized, and the dose needed to achieve a pharmacokinetic-pharmacodynamic (PK-PD) target has yet to be established because its efficacy is associated with the area under the plasma drug concentration time curve (AUC(24))/minimum inhibitory concentration (MIC) ratio. The present study aimed to define the pharmacokinetic parameters of intravenous linezolid in pediatric patients and assess the rationale for the approved dosage recommendations. Linezolid was safe, tolerated well, and clinically effective for treating Gram-positive bacteria in five pediatric patients (3-11 years). The mean values for the volume of distribution, and total clearance (CL) in a one-compartment model were estimated to be 0.646 +/- 0.239 l/kg and 0.171 +/- 0.068 1/h/kg, respectively (mean +/- S.D.). Based on this analysis, the AUC(24) and trough drug concentration in plasma (C-min) for linezolid doses were predicted to be 175.4 mu g h/ml and 3.4 mu g/ml for 30 mg/kg/day, 204.7 mu g h/ml and 4.3 mu g/ml for 35 mg/kg/day, and 2632 mu g h/ml and 6.2 mu g/ml for 45 mg/kg/day, respectively. Taking into account that AUC(24) should be >= 200 mu g h/ml for MIC of 2.0 mu g/ml (to achieve an AUC(24)/MIC ratio of >= 100) and C-min should be approximately 7 mu g/ml (to avoid thrombocytopenia), we consider the approved dosage of 30 mg/kg/day to be fundamentally rational, but can be underdosed against bacteria with MIC of 2.0 mu g/ml; therefore, a dose of 35-45 mg/kg/day is more appropriate to ensure the efficacy and safety of linezolid in pediatric patients. (C) 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

• Access to Document (DOI)

カラゲニン足蹠浮腫モデルを用いた各種ケトプロフェンテープ剤の抗炎症効果比較.

松元一明, 河野倫也, 杉山哲也, 坂本靖宜, 島田亜由美, 黒田裕子, 寺島朝子, 前澤佳代子, 木津純子.

医療薬学 40   672 - 676 2014年11月

研究論文（学術雑誌）, 共著, 査読有り

Factors affecting treatment and recurrence of Clostridium difficile infections.

Matsumoto Kazuaki, Kanazawa Naoko, Shigemi Akari, Ikawa Kazuro, Morikawa Norifumi, Toyoyasu Koriyama, Orita Michiyo, Kawamura Hideki, Tokuda Koichi, Nishi Junichiro, Takeda Yasuo.

BIOLOGICAL & PHARMACEUTICAL BULLETIN （PHARMACEUTICAL SOC JAPAN）  37 （ 11 ） 1811 - 1815 2014年11月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  0918-6158

　概要を見る

The antimicrobial agents vancomycin and metronidazole have been used to treat Clostridium difficile infections (CDIs). However, it remains unclear why patients are at risk of treatment failure and recurrence. Therefore, this study retrospectively examined 98 patients with CDIs who were diagnosed based on the detection of toxin-positive C. difficile to determine the risk factors affecting drug treatment responses and the recurrence of CDI. No significant difference was observed in the cure rate or dosage between the vancomycin and metronidazole groups. The 90-d mortality rate and total number of drugs associated with CDIs, including antiinfective agents used within 2 months before the detection of toxin-positive C. difficile, were significantly lower in the treatment success group than in the failure group. The total number of antiinfective agents and gastric acid-suppressive agents used during CDI therapy was also significantly lower in the success group than in the failure group. The period from the completion of CDI therapy to restarting the administration of anticancer agents and steroids was significantly longer in patients without than in patients with recurrence. These results indicate that the total number of drugs associated with CDIs should be minimized to reduce the risk of CDIs, that not only antibiotics but also gastric acid-suppressive agents should be discontinued during CDI therapy to increase therapeutic efficacy, and that the use of anticancer agents and steroids should be delayed as long as possible after patients are cured by CDI therapy to prevent recurrence.

複合型塩素系除菌・洗浄用製剤の安定性と色調の変化.

木津純子, 高木奏, 黒田裕子, 前澤佳代子, 松元一明, 堀誠治.

日本環境感染学会誌 29 （ 6 ） 411 - 416 2014年11月

研究論文（学術雑誌）, 査読有り

Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: A dosage strategy according to the trough concentration target and renal function in adult patients.

Matsumoto Kazuaki, Shigemi Akari, Takeshita Ayumi, Watanabe Erika, Yokoyama Yuta, Ikawa Kazuro, Morikawa Norifumi, Takeda Yasuo.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS （ELSEVIER SCIENCE BV）  44 （ 3 ） 242 - 247 2014年09月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  0924-8579

　概要を見る

The pharmacokinetic/pharmacodynamic (PK/PD) index for the efficacy of linezolid is a 24-h area under the plasma drug concentration-time curve (AUC(24))/minimum inhibitory concentration (MIC) ratio of >= 100. The main adverse event associated with administration of linezolid is thrombocytopenia. Therefore, the aims of the present study were to define PD thresholds that would minimise linezolid-induced thrombocytopenia and to perform a population PK analysis to identify factors influencing the pharmacokinetics of linezolid. Population PK analysis revealed that creatinine clearance (CLCr) significantly affected linezolid pharmacokinetics: the mean parameter estimate of drug clearance (CL; in L/h)= 0.0258 x CLCr + 2.03. A strong correlation (r=0.970) was found between AUC(24) and trough plasma concentrations (C.) [AUC(24)=18.2 x C-min + 134.4]. The Cmin value for AUC(24)=200 (in the case of MIC=2 mu g/mL) was estimated to be 3.6 mu g/mL. Regarding safety, Cmin was a significant predictor of thrombocytopenia during treatment, and its threshold to minimise linezolid-induced thrombocytopenia was 8.2 mu g/mL. A Kaplan-Meier plot revealed that the median time from initiation of therapy to the development of thrombocytopenia was 15 days. Therefore, the target C. range was 3.6-8.2 mu g/mL. The following formula to achieve a target C. in patients with different degrees of renal function was proposed based on these results: initial daily dose (mg/day) = CL x AUC(24) = (0.0258 x CLCr + 2.03) x (18.2 x C-min + 134.4). This recommended initial dosage and subsequent dosage adjustment for the target concentration range should avoid adverse events, thereby enabling effective linezolid-based therapies to be continued. (C) 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

• Access to Document (DOI)

Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.

Yokoyama Yuta, Matsumoto Kazuaki, Ikawa Kazuro, Watanabe Erika, Shigemi Akari, Umezaki Yasuhiro, Nakamura Koyo, Ueno Keiichiro, Morikawa Norifumi, Takeda Yasuo.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 43 （ 6 ） 547 - 552 2014年06月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  0924-8579

Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Okada Kenji, Kimura Toshimi, Mikamo Hiroshige, Kasahara Kei, Seki Masafumi, Takakura Shunji, Tokimatsu Issei, Ohmagari Norio, Takahashi Yoshiko, Matsumoto Kazuaki, Igarashi Masahiro, Kobayashi Masahiro, Hamada Yukihiro, Mochizuki Takahiro, Kimura Masao, Nishi Yoshifumi, Tanigawara Yusuke, Takesue Yoshio.

JOURNAL OF INFECTION AND CHEMOTHERAPY （ELSEVIER SCIENCE BV）  20 （ 1 ） 1 - 5 2014年01月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  1341-321X

　概要を見る

Arbekacin (ABK) was approved and widely used in Japan for treatment of patients infected with MRSA, and TDM was introduced in clinical practice. The Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring decided to develop a clinical practice guidelines for TDM of ABK for the following reasons. First, although the daily dose of 150-200 mg was approved in Japan, recent PR-PD studies revealed that higher serum concentration is required to achieve better clinical efficacy and several findings concerning the usefulness of higher dosage regimen have obtained recently. Second, although maximal concentrations that obtained immediately after the end of administration (C-max) was generally adopted, the serum concentration at 1 h after initiation of administration [peak serum concentration (C-peak)] proved to be more suitable as an efficacy indicator of aminoglycosides. Lastly, as ABK is approved only in Japan, no international practice guideline for TDM has not been available in ABK to date. This guideline evaluated the scientific data associated with serum ABK monitoring and provided recommendations based on the available evidence. Potential limitations of this guideline, however, include the findings that few prospective clinical trials of TDM of ABK are available in the treatment of MRSA infections and that most of the published literature describes observational studies. (C) 2013, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

• Access to Document (DOI)

九州山口地区における基質拡張型βラクタマーゼ産生菌の検出状況と抗菌薬使用状況に関する合同調査.

室高広, 北原隆志, 伊東弘樹, 入江利行, 野中敏治, 藤井裕史, 松元一明, 山崎博史, 柳原克紀, 佐々木均.

日本環境感染学会誌 29   32 - 39 2014年01月

研究論文（学術雑誌）, 共著, 査読有り

Development of Initial Loading Procedure for Teicoplanin in Critically Ill Patients with Severe Infections.

Matsumoto Kazuaki, Kanazawa Naoko, Watanabe Erika, Yokoyama Yuta, Fukamizu Tomohide, Shimodozono Yoshihiro, Maeda Chiharu, Yasuda Tomotsugu, kakihana Yasuyuki, Ikawa Kazuro, Morikawa Norifumi, Takeda Yasuo.

BIOLOGICAL & PHARMACEUTICAL BULLETIN 36 （ 6 ） 1024 - 1026 2013年06月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  0918-6158

Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Matsumoto Kazuaki, Takesue Yoshio, Ohmagari Norio, Mochizuki Takahiro, Mikamo Hiroshige, Seki Masafumi, Takakura Shunji, Tokimatsu Issei, Takahashi Yoshiko, Kasahara Kei, Okada Kenji, Igarashi Masahiro, Kobayashi Masahiro, Hamada Yukihiro, Kimura Masao, Nishi Yoshifumi, Tanigawara Yusuke, Kimura Toshimi.

JOURNAL OF INFECTION AND CHEMOTHERAPY 19 （ 3 ） 365 - 380 2013年06月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  1341-321X

• Access to Document (DOI)

Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Hamada Yukihiro, Tokimatsu Issei, Mikamo Hiroshige, Kimura Masao, Seki Masafumi, Takakura Shunji, Ohmagari Norio, Takahashi Yoshiko, Kasahara Kei, Matsumoto Kazuaki, Okada Kenji, Igarashi Masahiro, Kobayashi Masahiro, Mochizuki Takahiro, Nishi Yoshifumi, Tanigawara Yusuke, Kimura Toshimi, Takesue Yoshio.

JOURNAL OF INFECTION AND CHEMOTHERAPY 19 （ 3 ） 381 - 392 2013年06月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  1341-321X

• Access to Document (DOI)